# **Supplementary Material**

## **Table of contents:**

- 1. Supplementary Table 1 Bone Marrow cellularity estimates obtained from literature
- 2. Supplementary Figures 1-3 Sum of squares as a function of different parameter values (transit time, loss rate and R).
- 3. Supplementary Figure 4 Effect of secondary purification on neutrophil DNA enrichment
- 4. Supplementary Text 1. Deuterium-labeled glucose plasma exposure
- 5. Supplementary Text 2. Comparison between model used by Pillay et al and the two-compartment model developed here
- 6. Supplementary Material References

# **Supplementary Tables**

## **Supplementary Table 1. Bone Marrow cellularity estimates retrieved from literature for human and mice using**

## **different techniques**



# **Supplementary Figures**



**Supplementary Figure 1: Sum of squares as a function of marrow transit time.**

Neutrophil loss rate from blood (and  $b_w$  in the case of labeling with water) were free parameters whereas marrow transit time was fixed to given values (abscise axis). The minima indicate the numerically most-plausible scenarios. The first 7 panels (Subjects C36R-C50) are from subjects labeled with deuterated glucose; the remaining 9 panels (Subjects A-E and DW04-DW11) are from subjects labeled with heavy water.



### **Supplementary Figure 2: Sum of squares as a function of half-life.**

Marrow transit time (and  $b_w$  in the case of labeling with water) were free parameter whereas loss rate from blood was fixed to the given values (abscise axis, expressed as a half-life). The minima indicate the numerically mostplausible scenarios. The first 7 panels (Subjects C36R-C50) are from subjects labeled with deuterated glucose; the remaining 9 panels (Subjects A-E and DW04-DW11) are from subjects labeled with heavy water.



**Supplementary Figure 3: Sum of squares and half-life estimates as a function of R.**

The model was simultaneously fitted to data from the 9w heavy water labeling study, 10h and 3h deuterium-labeled glucose labeling study. Marrow transit-time and neutrophil loss rate from blood were free parameters, whereas R was fixed to given values (see abscises axis). The resulting sum of squares and half-life estimates (for both bone marrow neutrophil precursors and blood neutrophils) are plotted. The minima in the SSQ indicate the numerically most-plausible scenarios.



In two subjects, C59 and C60, aliquots were further purified by CD16 antibody-coated magnetic bead adhesion (Miltenyi Biotec, UK) and analyzed in parallel with cells purified by gradient-separation alone. Neutrophil DNA Enrichment curves for C59 (a) and C60 (b). Cells were separated by gradient-centrifugation in Polymorphprep, either alone (blue lines) or with a subsequent CD16 microbead separation (red lines).

## **Supplementary Text 1: Deuterium-labeled glucose plasma exposure**

For the 3h, 4h and 10h labelling protocols  $U_t$  was approximated by the following function:

$$
U_t = MAPE_{(0-\tau)} \qquad \text{if } (t \le \tau)
$$
  

$$
U_t = APE_{\tau} \cdot e^{-k_d \cdot (t-\tau)} \qquad \text{if } (t > \tau)
$$

where τ is the time of the last dose, MAPE<sub>(0-τ)</sub> is the mean plasma enrichment between time 0 and τ (calculated as the area under the plasma enrichment curve divided by τ), APE<sub>τ</sub> is the plasma enrichment at time τ and k<sub>d</sub> is the elimination constant of glucose for each individual. Parameter values are given in Supplementary Table 2.

For the bolus-dose labelling protocol,  $U_t$  was approximated by interpolating between each data point (see Supplementary Figure 5).

<b>Identifier</b>	<b>MAPE (%)</b>	APE_tau (%)	$k_d$ (h-1)	Tau, $\tau$ (h)
C <sub>36</sub> R	27.3	22.4	0.856	10
C41	41.6	39.9	0.589	10
C42	39.8	49.5	0.580	4
C46	25.9	33.9	0.468	3
C48	31.8	40.5	0.596	3
C49	37.7	27.9	0.610	3
C50	12.0	20.9	0.371	3

**Supplementary Table 2. Exposure parameters for individuals from the 3h, 4h and 10h glucose labelling protocols**

## **Supplementary Figure 5. Deuterium-labeled glucose exposure curves for C59 and C60**



Graphs show plasma glucose deuterium enrichment for subjects C59 and C60. For C59, points between 3h and 6h were estimated using linear interpolation on a log linear scale. After 7h label exposure was considered to be negligible.

# **Supplementary Text 2: Comparison between model used by Pillay** *et al* **and the two-compartment model developed here**

### **Pillay et al. model**

The model used by Pillay et al. [\(10\)](#page-9-9) describes granulocyte turnover in terms of proliferation and death in a single homogenous compartment at steady state. The equation is as follows:

$$
\frac{dL_b}{dt} = z \cdot b \cdot U_{(t-\Delta)} - z \cdot L_b \tag{1}
$$

where b is the heavy water normalizing factor, z is the proliferation/death rate (equal at steady-state) and Ut is the label availability function at time t, in this equation lagged by a parameter Δ.

Consider a square pulse of label such that  $U_t$  is a step function ( $U_t$ =A if time is smaller or equal than the labelling time (τ), and 0 once label administration has finished). In such a scenario equation 1a can be discretized to the following:

$$
\frac{dL_b}{dt} = 0 \t\t if \t \le \Delta \t (2a)
$$
\n
$$
\frac{dL_b}{dt} = z \cdot b \cdot A - z \cdot L_b \t\t if \t \Delta < t < \tau + \Delta \t (2b)
$$
\n
$$
\frac{dL_b}{dt} = -z \cdot L_b \t\t if \t \ge \tau + \Delta \t (2c)
$$

#### **Two-compartment model**

Our model, in contrast to that of Pillay et al. model, describes granulocyte turnover using two compartments (see main text Figure 1). Model equations are the following:

$$
\frac{dL_p}{dt} = z \cdot R \cdot b \cdot U_{(t)} - z \cdot R \cdot L_p \tag{3a}
$$

$$
\frac{dL_b}{dt} = z \cdot L_p(t - \Delta) - z \cdot L_b \tag{3b}
$$

Assuming a step function for  $U_t$ , as before, and solving 3a analytically we obtain equations 4a and 4b.

$$
L_p(t) = b \cdot A \cdot (1 - e^{-z \cdot R \cdot t}) \qquad \text{if } t \le \tau \qquad (4a)
$$

$$
L_p(t) = b \cdot A \cdot (1 - e^{-z \cdot R \cdot \tau}) e^{-R \cdot z(t - \tau)} \qquad \text{if } t > \tau \qquad (4b)
$$

Substituting these into 3b we obtain

$$
\frac{dL_b}{dt} = 0 \qquad \text{if } t \le \Delta \qquad (5a)
$$
\n
$$
\frac{dL_b}{dt} = z \cdot b \cdot A \cdot \left(1 - e^{-z \cdot R \cdot (t - \Delta)}\right) - z \cdot L_b \qquad \text{if } \Delta < t < \tau + \Delta \qquad (5b)
$$
\n
$$
\frac{dL_b}{dt} = z \cdot b \cdot A \cdot \left(1 - e^{-z \cdot R \cdot \tau}\right) e^{-R \cdot z \cdot (t - \tau - \Delta)} - z \cdot L_b \qquad \text{if } t > \tau + \Delta \qquad (5c)
$$

Comparing (5a)-(5c) with (2a)-(2c), we see that as R tends to infinity our model is mathematically identical to the model of Pillay *et al.* It can thus be seen that Pillay *et al* implicitly assume that R is large, an assumption which appears to be at odds with current knowledge of the system. Furthermore, it can be seen (Supplementary Figure 3) that as R is increased the estimate of the circulating half-life increases, explaining why Pillay *et al* obtained such large estimates for the half life.

#### **Supplementary Material References**

<span id="page-9-0"></span>1. Colvin G, Lambert J, Abedi M, Hsieh C, Carlson J, Stewart F, et al. Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology. Leukemia. 2004;18(3):575- 83.

<span id="page-9-1"></span>2. Boggs D. The total marrow mass of the mouse: a simplified method of measurement. American journal of hematology. 1984;16(3):277-86.

<span id="page-9-2"></span>3. Pegg D. A quantitative study of bone marrow grafting: Implications for human bone marrow infusion. British journal of cancer. 1962;16(3):400.

<span id="page-9-3"></span>4. Osgood EE. Number and distribution of human hemic cells. Blood. 1954;9(12):1141-54.

<span id="page-9-4"></span>5. Patt HM. A consideration of myeloid-erythroid balance in man. Blood. 1957;12(9):777-87.

<span id="page-9-5"></span>6. Donohue DM, Gabrio BW, Finch CA. Quantitative measurement of hematopoietic cells of the marrow. Journal of Clinical Investigation. 1958;37(11):1564.

<span id="page-9-6"></span>7. Harrison W. The total cellularity of the bone marrow in man. Journal of clinical pathology. 1962;15(3):254-9.

<span id="page-9-7"></span>8. Skårberg KO. Cellularity and cell proliferation rates in human bone marrow. Acta medica Scandinavica. 1974;195(1‐6):291-9.

<span id="page-9-8"></span>9. Suit H. A technique for estimating the bone marrow cellularity in vivo using 59Fe. Journal of clinical pathology. 1957;10(3):267.

<span id="page-9-9"></span>10. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JA, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116(4):625-7.

11. Jilma B, Hergovich N, Stohlawetz P, Eichler HG, Bauer P, Wagner O. Circadian variation of granulocyte colony stimulating factor levels in man. British journal of haematology. 1999;106(2):368-70.

12. Akbulut H, Icli F, Büyükcelik A, Akbulut KG, Demirci S. The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. Journal of pineal research. 1999;26(1):1-8.

13. Smaaland R, Laerum O, Lote K, Sletvold O, Sothern R, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 1991;77(12):2603-11.

14. Smaaland R, Laerum O, Sothern R, Sletvold O, Bjerknes R, Lote K. Colony-forming unit-granulocytemacrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood. 1992;79(9):2281-7.

15. Granda TG, Liu X-H, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. The FASEB Journal. 2005;19(2):304-6.

16. Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chèvre R, Noelia A, et al. Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell. 2013;153(5):1025-35.

17. Furze RC, Rankin SM. The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse. The FASEB Journal. 2008;22(9):3111-9.

18. Slayter KL, Ludwig EA, Lew KH, Middleton E, Ferry JJ, Jusko WJ. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical Pharmacology & Therapeutics. 1996;59(3):312-21.

10